Rhumbline Advisers Boosts Holdings in Cryoport, Inc. (NASDAQ:CYRX)

Rhumbline Advisers increased its holdings in Cryoport, Inc. (NASDAQ:CYRX) by 2.9% in the 4th quarter, according to its most recent filing with the SEC. The institutional investor owned 63,284 shares of the company’s stock after buying an additional 1,764 shares during the quarter. Rhumbline Advisers owned about 0.13% of Cryoport worth $492,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of CYRX. Avanza Fonder AB bought a new stake in shares of Cryoport during the 4th quarter valued at about $64,000. Dynamic Technology Lab Private Ltd purchased a new position in shares of Cryoport during the 3rd quarter valued at about $82,000. Intech Investment Management LLC purchased a new position in shares of Cryoport during the 3rd quarter valued at about $105,000. NRI Wealth Management LC purchased a new position in shares of Cryoport during the 4th quarter valued at about $149,000. Finally, Quest Partners LLC lifted its holdings in Cryoport by 168.5% in the 3rd quarter. Quest Partners LLC now owns 29,083 shares of the company’s stock worth $236,000 after purchasing an additional 18,252 shares in the last quarter. 92.90% of the stock is currently owned by institutional investors.

Cryoport Trading Down 6.5 %

Cryoport stock opened at $6.23 on Friday. The stock has a 50-day moving average of $7.25 and a two-hundred day moving average of $7.58. The company has a debt-to-equity ratio of 0.48, a quick ratio of 5.32 and a current ratio of 5.70. Cryoport, Inc. has a one year low of $4.58 and a one year high of $20.10. The stock has a market cap of $307.96 million, a PE ratio of -1.84 and a beta of 1.67.

Cryoport (NASDAQ:CYRX) last announced its quarterly earnings data on Tuesday, March 4th. The company reported ($0.42) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.09). The firm had revenue of $59.53 million during the quarter, compared to analyst estimates of $58.71 million. Cryoport had a negative net margin of 70.08% and a negative return on equity of 13.35%. During the same period in the prior year, the company posted ($0.29) earnings per share. On average, research analysts anticipate that Cryoport, Inc. will post -0.99 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts have recently issued reports on the company. Needham & Company LLC reaffirmed a “buy” rating and set a $11.00 price objective on shares of Cryoport in a report on Wednesday. Guggenheim initiated coverage on Cryoport in a research report on Thursday, December 19th. They set a “buy” rating and a $11.00 price target on the stock. Three equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat, Cryoport presently has a consensus rating of “Moderate Buy” and a consensus price target of $12.29.

About Cryoport

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.